阿什肯纳兹犹太人患者的多基因panel检测在多个非BRCA癌症相关基因中产出高比例的可操作突变
单中心回顾性分析2013年6月至2015年1月接受多基因panel检测或靶向BRCA1/2检测的患者,比较阿什肯纳兹犹太人与非阿什肯纳兹犹太人。阿什肯纳兹犹太人接受基因检测者中25/183(14%)检出突变,其中24/25(96%)为可操作突变,17/25(68%)位于非BRCA1/2基因。作者认为该人群多数结果临床可操作且常涉及非BRCA1/2基因,建议考虑多基因panel检测。
要点
- 阿什肯纳兹犹太人接受基因检测者中25/183(14%)检出突变,24/25(96%)为可操作突变。
- 阿什肯纳兹犹太人25例突变中17例(68%)位于非BRCA1/2基因。
- 作者建议在该人群考虑多基因panel检测,因多数结果临床可操作且常为非BRCA1/2基因。
核心结论
- 作者认为,尽管传统上许多阿什肯纳兹犹太人接受靶向BRCA1/2检测,数据提示应考虑多基因panel检测,因多数结果临床可操作且常位于非BRCA1/2基因。
研究设计与样本
- 单中心回顾性研究,回顾2013年6月至2015年1月接受多基因panel检测和靶向BRCA1/2检测患者的病历。
- 454例患者接受多基因panel筛查,其中138例为阿什肯纳兹犹太人;同期靶向BRCA1/2检测纳入103例患者。
- 患者中位年龄52岁;354例(78%)有个人癌症史,包括乳腺癌251例、卵巢癌49例、子宫癌26例、结直肠癌20例。
主要发现
- 56例患者中检出62个突变,196例患者中检出291个意义不明变异。
- 56例有突变患者中51例(91%)为可操作突变。
- 阿什肯纳兹犹太人通过多基因panel检出20个突变,其中18个位于非BRCA1/2基因。
- 同期靶向BRCA1/2检测103例中检出6个BRCA1/2突变,均发生于阿什肯纳兹犹太人。
- 阿什肯纳兹犹太人接受基因检测者中25/183(14%)检出突变,24/25(96%)为可操作突变,17/25(68%)位于非BRCA1/2基因。
关键数值与推荐
- 可操作性依据美国国家综合癌症网络(NCCN)指南、共识声明及专家意见(针对指南未涉及的基因)判定。
临床怎么用
- 作者认为,阿什肯纳兹犹太人可考虑多基因panel检测,因多数结果临床可操作且常涉及非BRCA1/2基因。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the results of multigene panel testing among Ashkenazi Jewish compared with non-Ashkenazi Jewish patients. METHODS: We reviewed the medical records for all patients who underwent multigene panel testing and targeted BRCA1/2 testing at a single institution between 6/2013-1/2015. Clinical actionability for identified pathogenic mutations was characterized based on the National Comprehensive Cancer Network (NCCN) guidelines and consensus statements and expert opinion for genes not addressed by these guidelines. RESULTS: Four hundred and fifty-four patients underwent multigene panel screening, including 138 Ashkenazi Jewish patients. The median patient age was fifty-two years. Three hundred and fifty-four patients (78%) had a personal history of cancer. Two hundred and fifty-one patients had breast cancer, 49, ovarian cancer, 26, uterine cancer and 20, colorectal cancer. We identified 62 mutations in 56 patients and 291 variants of uncertain significance in 196 patients. Among the 56 patients with mutations, 51 (91%) had actionable mutations. Twenty mutations were identified by multigene panels among Ashkenazi Jewish patients, 18 of which were in genes other than BRCA1/2. A review of targeted BRCA1/2 testing performed over the same study period included 103 patients and identified six mutations in BRCA1/2, all of which occurred in Ashkenazi Jewish patients. Among all Ashkenazi Jewish patients undergoing genetic testing, 25/183 (14%) had a mutation, 24/25 of which were actionable (96%) and 17/25 patients (68%) had mutations in non BRCA1/2 genes. CONCLUSIONS: With the rapid acceptance of multigene panels there is a pressing need to understand how this testing will affect patient management. While traditionally many Ashkenazi Jewish patients have undergone targeted BRCA1/2 testing, our data suggest consideration of multigene panels in this population as the majority of the results are clinically actionable and often in genes other than BRCA1/2.
引用
- Frey MK, Sandler G, Sobolev R, et al. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes. Gynecol Oncol. 2017. PMID: 28495237. doi:10.1016/j.ygyno.2017.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。